Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

Abstract: Provided herein are systems and methods for radiolabeling of recombinant Adeno-Associated Virus (rAAV) with radioactive iodine. Also provided are methods for in vivo imaging and treatment using the radiolabeled rAAV.

Abstract: Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence: (a) administering to a subject about 3 mCi Tl201 thallous chloride; (b) allowing said subject to rest; (c) radioimaging a heart of said subject; (d) subjecting said subject to a physical stress; (e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and (f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

Abstract: Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence: (a) administering to a subject about 3 mCi Tl201 thallous chloride; (b) allowing said subject to rest; (c) radioimaging a heart of said subject; (d) subjecting said subject to a physical stress; (e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and (f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

Abstract: A method of imaging, comprising: (a) providing an isotope at a low dosage in a body of a patient; (b) receiving radiation generated by said isotope from said body using a radiation camera; and (c) reconstructing a 3D distribution of said isotope from said received radiation, wherein the dosage is less than ? of a standard dose set forth in Table 5.

Abstract: A method of radioactive-emission-measurement. The method comprises providing a camera for the detection of single emissions, which defines proximal and distal ends. The camera is configured for enabling a reconstruction of a volumetric image having a line spread function of less than 7 mm Full Width Half Maximum (FWHM) when given a substantially line source of radioactive emission, with an activity of 5 mCi, within a region-of-interest volume, at a distance of at least 100 mm from said distal end, with air being substantially the only operating medium. The method further comprises detecting at least 1 of every 5000 photons, emitted from at least one radioactive-emission source, located within a certain region-of-interest volume, using the camera, and reconstructing a volumetric radioactive-emission image from the detected photons.

Abstract: Radioimaging methods, devices and radiopharmaceuticals therefor.

Abstract: Radioimaging methods, devices and radiopharmaceuticals therefor.

Abstract: A method of imaging, including receiving radioactive radiation from a body; reconstructing a 3D SPECT image of a distribution of radiation in at least one voxel of said body; and reconstructing a dynamic change in radiation in said voxel, as an updated image, at a rate of faster than one change per 5 minutes, wherein said reconstructed image is a clinically useful image including a resolution of 10 mm or better for a voxel volume of at least 5 cm in diameter and a contrast to background ratio of radiation of at least 2:1.

Abstract: An electronic storage medium that comprises at least one radiopharmaceutical identity, SPECT measured values of at least one radiopharmaceutical kinetic parameter of a flow rate across a tissue membrane, for the radiopharmaceutical, and a set of instructions for associating the at least one radiopharmaceutical kinetic parameter with a disease signature.

Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

Abstract: Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence: (a) administering to a subject about 3 mCi Tl201 thallous chloride; (b) allowing said subject to rest; (c) radioimaging a heart of said subject; (d) subjecting said subject to a physical stress; (e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and (f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

Abstract: Radioimaging methods, devices and radiopharmaceuticals therefor.

Abstract: Radioimaging methods, devices and radiopharmaceuticals therefor.

Abstract: Radioimaging methods, devices and radiopharmaceuticals therefor.

Abstract: Radioimaging methods, devices and radiopharmaceuticals therefor.

Abstract: Radioimaging methods, devices and radiopharmaceuticals therefor.

Abstract: The present invention relates to the capabilities of a highly sensitive radioactive-emission camera, a result of a meticulous search for the many different effects that combine synergistically to increase sensitivity and spatial, spectral, and time resolutions. The new camera opens a new realm in SPECT-type imaging, making it viable for dynamic studies, the use of radiopharmaceutical cocktails, molecular imaging, dosimetry and other studies requiring the high sensitivity and resolutions. In particular, the new camera opens the door to SPECT expert system, examples for which are provided. The expert system relates to defining disease signatures for automatic diagnosis, preferably, based on a multi-parameter vector, preferably, based on kinetic radiopharmaceutical values. Additionally or alternatively, based on simultaneous administration of multiple isotopes.